An AllTrials project

NCT01873833: A trial that was reported late by University of Southern California

This trial has reported, although it was 254 days late in doing so.

Full data

Full entry on NCT01873833
Title Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Results Status Reported (late)
ACT or pACT? This is what FDAAA officially calls a "probable Applicable Clinical Trial"
Start date July 29, 2013
Completion date March 2, 2021
Required reporting date March 2, 2022, midnight
Actual reporting date Nov. 11, 2022
Date last checked at Feb. 9, 2024
Days late 254